(1) In agreement with the review data, therapy with MgSO4, with or without a β2-agonist, was superior to therapy with β2-agonist alone (standardized mean difference [SMD], 0.30; 95% confidence interval [CI], 0.05 to 0.55; p = 0.02; five studies) with no between-study heterogeneity. However, a careful inspection of the data shows that pulmonary function values of the study of Bessmertny et al2 were entered erroneously: in Table 2 and Figure 2 of their study (at 65 min), the mean values for FEV1 (percentage of predicted) are 68 ± 22.5% for the control group (not for the treatment group as appeared in Fig 1 of the review) and 63 ± 20.6% for the MgSO4 group (not for the control group). This mistake changes the results dramatically (Fig 1
Thus, the effect of aerosolized MgSO4 on posttreatment lung function is not superior to therapy with β2-agonists alone (SMD, 0.16; 95% CI, − 0.08 to 0.41), with low-to-moderate heterogeneity (İ2 = 40.8%). The effect was similar when therapy with β-agonists and MgSO4 was compared with a β-agonist alone (four studies): SMD, 0.21; 95% CI, − 0.05 to 0.48; p = 0.11, with low-to-moderate heterogeneity again (İ2 = 47.6%).